Fig. 2: Pharmacokinetic profiles of dacomitinib and PD-0325901. | British Journal of Cancer

Fig. 2: Pharmacokinetic profiles of dacomitinib and PD-0325901.

From: Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Fig. 2: Pharmacokinetic profiles of dacomitinib and PD-0325901.

All figures: plasma-concentration–time curves of mean plasma levels per dose level. DL, dose level; 21/7, 21 days on/7 days off; 4/3 4 days on/3 days off; 5/2 5 days on/2 days off. a Dacomitinib per dose level: cycle 1 day 1 (left) and cycle 2 day 1, or the last day of concomitant use of both drugs for intermittent dosing (right). b PD-0324901 per dose level: cycle 1 day 1 (left) and cycle 2 day 1, or the last day of concomitant use of both drugs for intermittent dosing (right).

Back to article page